nk-92
Cell therapyexperimental
Clinical trial activity
26 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
21
Phase 2
23
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2005 (NCT00990717)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Carcinoma, Merkel Cell · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Squamous Cell · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Chordoma · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Glioblastoma · Phase 1
- Hodgkin Disease · Phase 1
- Leukemia · Phase 1
- Lymphoma · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Multiple Myeloma · Phase 1
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- nk-92
- nk-92 cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03574649 | Phase 2 | Sep 30, 2018 | NantWorks |
| NCT03554109 | Phase 2 | Sep 30, 2018 | NantWorks |
| NCT03563144 | Phase 2 | Aug 31, 2018 | NantWorks |
| NCT03647423 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2018 | NantWorks |
| NCT03586869 | Phase 1/Phase 2 (Phase 2) | Jul 28, 2018 | NantWorks |
| NCT03563170 | Phase 1/Phase 2 (Phase 2) | May 25, 2018 | NantWorks |
| NCT03563157 | Phase 1/Phase 2 (Phase 2) | May 25, 2018 | NantWorks |
| NCT03387085 | Phase 1/Phase 2 (Phase 2) | Mar 16, 2018 | NantWorks |
| NCT03387111 | Phase 1/Phase 2 (Phase 2) | Jan 13, 2018 | NantWorks |
| NCT03387098 | Phase 1/Phase 2 (Phase 2) | Jan 2, 2018 | NantWorks |
| NCT03197584 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2017 | NantWorks |
| NCT03197571 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2017 | NantWorks |
| NCT03383978 | Phase 1 | Dec 1, 2017 | DRK Blutspendedienst Baden-Württemberg-Hessen gGmbH, Georg-Speyer-Haus, J. W. Goethe University, LOEWE Center for Cell and Gene Therapy, NantWorks |
| NCT03329248 | Phase 1/Phase 2 (Phase 2) | Nov 6, 2017 | NantWorks |
| NCT03175666 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2017 | NantCell, Inc. |
| NCT03169777 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2017 | NantCell, Inc. |
| NCT03169764 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2017 | NantCell, Inc. |
| NCT03169738 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2017 | NantCell, Inc. |
| NCT03167177 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2017 | NantCell, Inc. |
| NCT03167164 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2017 | NantCell, Inc. |
Showing 20 of 26 trials
Page 1 / 2
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NantWorks | For profit | 16 | 15 | 2 | 2015 |
| NantCell, Inc. | For profit | 8 | 8 | 1 | 2017 |
| Catholic University of Korea | Academic/Hospital | 1 | 1 | 1 | 2015 |
| DRK Blutspendedienst Baden-Württemberg-Hessen gGmbH | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Georg-Speyer-Haus | Academic/Hospital | 1 | 0 | 1 | 2017 |
| J. W. Goethe University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| LOEWE Center for Cell and Gene Therapy | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2005 |
8 organizations
Page 1 / 1